SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Peter Karayiannis, Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis, Scientifica, 2012, 2012, 1

    CrossRef

  2. 2
    Yong Han Paik, Ja Kyung Kim, Do Young Kim, Jun Yong Park, Sang Hoon Ahn, Kwang-Hyub Han, Chae Yoon Chon, Kwan Sik Lee, Clinical Efficacy of a 24-months Course of Lamivudine Therapy in Patients with HBeAg Negative Chronic Hepatitis B: A Long-term Prospective Study, Journal of Korean Medical Science, 2010, 25, 6, 882

    CrossRef

  3. 3
    José M. Sánchez-Tapias, Fármacos para el tratamiento de la hepatitis B crónica, Gastroenterología y Hepatología, 2008, 31, 3, 120

    CrossRef

  4. 4
    Erik H.C.J. Buster, Solko W. Schalm, Harry L.A. Janssen, Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues, Best Practice & Research Clinical Gastroenterology, 2008, 22, 6, 1093

    CrossRef

  5. 5
    J. Davis, Preventing hepatitis B virus reactivation following immunosuppressive therapy, Internal Medicine Journal, 2008, 38, 7
  6. 6
    Ramón Planas, Rosa M. Morillas, Tratamiento de la infección por el virus de la hepatitis B. Estado actual y perspectivas, Gastroenterología y Hepatología, 2008, 31, 6, 349

    CrossRef

  7. 7
    Jules L Dienstag, Lee-Jen Wei, Dong Xu, Bruce Kreter, Cross-Study Analysis of the Relative Efficacies of Oral Antiviral Therapies for Chronic Hepatitis B Infection in Nucleoside-Naive Patients, Clinical Drug Investigation, 2007, 27, 1, 35

    CrossRef

  8. 8
    Fabien Zoulim, Emerging drugs for hepatitis B, Expert Opinion on Emerging Drugs, 2007, 12, 2, 199

    CrossRef

  9. 9
    W. F. LEEMANS, M. J. TER BORG, R. A. DE MAN, Review article: success and failure of nucleoside and nucleotide analogues in chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2007, 26,
  10. 10
    Fabien Zoulim, Antiviral therapy of chronic hepatitis B, Antiviral Research, 2006, 71, 2-3, 206

    CrossRef

  11. 11
    Gaetano Scotto, Emilio Palumbo, Vincenza Fazio, Donatella Concetta Cibelli, Annalisa Saracino, Alessandra Tartaglia, Gioacchino Angarano, Prolonged Lamivudine Treatment in Patients with Chronic Active Anti-HBe???Positive Hepatitis, American Journal of Therapeutics, 2006, 13, 3, 218

    CrossRef

  12. 12
    Florian van Bömmel, Bernhard Zöllner, Christoph Sarrazin, Ulrich Spengler, Dietrich Hüppe, Bernd Möller, Heinz-Hubert Feucht, Bertram Wiedenmann, Thomas Berg, Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy, Hepatology, 2006, 44, 2
  13. 13
    M. Buti, Tratamiento de la hepatitis crónica B HBeAg negativo, Gastroenterología y Hepatología, 2006, 29, 50

    CrossRef

  14. 14
    Fasiha Kanwal, Mary Farid, Paul Martin, Gary Chen, Ian M. Gralnek, Gareth S. Dulai, Brennan M. R. Spiegel, Treatment Alternatives for Hepatitis B Cirrhosis: A Cost-Effectiveness Analysis, The American Journal of Gastroenterology, 2006, 101, 9, 2076

    CrossRef

  15. 15
    T. Vassiliadis, N. Nikolaidis, O. Giouleme, K. Tziomalos, N. Grammatikos, K. Patsiaoura, P. Zezos, D. Gkisakis, K. Theodoropoulos, P. Katsinelos, E. Orfanou-Koumerkeridou, N. Eugenidis, Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2005, 21, 5
  16. 16
    M. Buti, R. Jardi, F. Rodriguez-Frias, A. Valdes, M. Schaper, R. Esteban, J. Guardia, Changes in different regions of hepatitis B virus gene in hepatitis B ‘e’ antigen-negative patients with chronic hepatitis B: the effect of long-term lamivudine therapy, Alimentary Pharmacology & Therapeutics, 2005, 21, 11
  17. 17
    Hari S. Conjeevaram, Disease status and therapeutic end points in hepatitis B, Current Hepatitis Reports, 2005, 4, 1, 5

    CrossRef

  18. 18
    Mario Rizzetto, Nicholas C. Tassopoulos, Robert D. Goldin, Rafael Esteban, Teresa Santantonio, E. Jenny Heathcote, Marco Lagget, Namrata K. Taak, Mary A. Woessner, Stephen D. Gardner, Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B, Journal of Hepatology, 2005, 42, 2, 173

    CrossRef

  19. 19
    NIKOLAOS L NIKOLAIDIS, OLGA I GIOULEME, KONSTANTINOS A TZIOMALOS, ADAMOS S SAVERIADIS, NIKOLAOS GRAMMATIKOS, PANAGIOTIS DOUKELIS, ANASTASIOS D VOUTSAS, THEMISTOKLIS VASSILIADIS, KALLIOPI PATSIAOURA, ELENI ORFANOU-KOUMERKERIDOU, AIKATERINI BALASKA, NIKOLAOS P EUGENIDIS, Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients, Journal of Gastroenterology and Hepatology, 2005, 20, 11
  20. 20
    Emmet B. Keeffe, Douglas T. Dieterich, Steve-huy B. Han, Ira M. Jacobson, Paul Martin, Eugene R. Schiff, Hillel Tobias, Teresa L. Wright, A treatment algorithm for the management of chronic hepatitis B virus infection in the United States, Clinical Gastroenterology and Hepatology, 2004, 2, 2, 87

    CrossRef

  21. 21
    Spilios Manolakopoulos, Stylianos Karatapanis, Jiannis Elefsiniotis, Nicoletta Mathou, Jiannis Vlachogiannakos, Elissabet Iliadou, Anastasios Kougioumtzan, Michalis Economou, Christos Triantos, Dimitrios Tzourmakliotis, Alec Avgerinos, Clinical Course of Lamivudine Monotherapy in Patients with Decompensated Cirrhosis due to HBeAg negative chronic HBV infection, The American Journal of Gastroenterology, 2004, 99, 1, 57

    CrossRef

  22. 22
    Peter Karayiannis, Current therapies for chronic hepatitis B virus infection, Expert Review of Anti-infective Therapy, 2004, 2, 5, 745

    CrossRef

  23. 23
    S. K. Fung, F. Wong, M. Hussain, A. S. F. Lok, Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B, Journal of Viral Hepatitis, 2004, 11, 5
  24. 24
    L. D. Saravolatz, D. M. Asmuth, H. H. Nguyen, G. P. Melcher, S. H. Cohen, R. B. Pollard, Treatments for Hepatitis B, Clinical Infectious Diseases, 2004, 39, 9, 1353

    CrossRef

  25. 25
    M Lagget, M Rizzetto, Current pharmacotherapy for the treatment of chronic hepatitis B, Expert Opinion on Pharmacotherapy, 2003, 4, 10, 1821

    CrossRef

  26. 26
    Marcello Persico, Fedele Antonio De Marino, Eliana Persico, Giovanni Di Giacomo Russo, Bruno Palmentieri, Roberto Torella, Lamivudine ‘as needed’: a novel therapeutic approach for Hße-minus chronic hepatitis, Journal of Hepatology, 2003, 39, 5, 880

    CrossRef

  27. 27
    Nicole D. Simpson, Peter W. Simpson, Ali M. Ahmed, Mindie H. Nguyen, Gabriel Garcia, Emmet B. Keeffe, Aijaz Ahmed, Prophylaxis Against Chemotherapy-Induced Reactivation of Hepatitis B Virus Infection With Lamivudine, Journal of Clinical Gastroenterology, 2003, 37, 1, 68

    CrossRef

  28. 28
    G. A. Niro, T. Santantonio, R. Fontana, M. Insalata, D. Facciorusso, F. Signorile, F. Perri, A. Guastadisegni, D. Gioffreda, O. Palmieri, G. Pastore, A. Andriulli, Re-treatment of patients with anti-HBe-positive chronic hepatitis B who relapsed after an initial course of lamivudine, Alimentary Pharmacology & Therapeutics, 2003, 18, 9
  29. 29
    Mario Rizzetto, Alfredo Marzano, Marco Lagget, Treatment of hepatitis B e antigen-negative chronic hepatitis B with lamivudine, Journal of Hepatology, 2003, 39, 168

    CrossRef